- Home
- PAM vs ARWR Comparison
PAM vs ARWR Comparison
Compare PAM & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAM | ARWR |
|---|---|---|
| Founded | 1945 | 2001 |
| Country | Argentina | United States |
| Employees | 1847 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.6B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | PAM | ARWR |
|---|---|---|
| Price | $94.09 | $61.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $92.75 | $56.00 |
| AVG Volume (30 Days) | 219.0K | ★ 2.7M |
| Earning Date | 11-04-2025 | 11-25-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $1,926,000,000.00 | $829,448,000.00 |
| Revenue This Year | $136,919.08 | N/A |
| Revenue Next Year | $36.38 | N/A |
| P/E Ratio | $16.12 | ★ N/A |
| Revenue Growth | N/A | ★ 23258.15 |
| 52 Week Low | $54.95 | $9.57 |
| 52 Week High | $97.55 | $67.14 |
Technical Indicators
Market Signals| Indicator | PAM | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 67.55 | 73.02 |
| Support Level | $89.01 | $37.06 |
| Resistance Level | $91.02 | $67.14 |
| Average True Range (ATR) | 3.33 | 4.54 |
| MACD | -0.27 | 2.02 |
| Stochastic Oscillator | 92.30 | 83.01 |
Price Performance
Historical ComparisonAbout PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.